Moomoo AI 已提取核心信息
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the original registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company is also preparing for the primary offering of up to 6,512,087 shares of common stock upon the exercise of warrants, and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. ProSomnus, Inc. is known for manufacturing precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock...Show More
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the original registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company is also preparing for the primary offering of up to 6,512,087 shares of common stock upon the exercise of warrants, and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. ProSomnus, Inc. is known for manufacturing precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock and public warrants are listed on the Nasdaq Global Market and Nasdaq Capital Market under the symbols 'OSA' and 'OSAAW', respectively. The closing prices for the common stock and public warrants as of January 29, 2024, were $0.82 and $0.035, respectively. ProSomnus has declared itself as an 'emerging growth company' and a 'smaller reporting company', which may allow it to comply with reduced public company reporting requirements for this and future filings.
2024年2月2日，特拉华州的一家公司ProSomnus, Inc. 向美国证券交易委员会（SEC）提交了S-3表格S-1的生效后修正案。该修正案旨在将原始注册声明转换为S-3表格的注册声明，并将先前注册的可转换票据股票从注册中删除，其中230,494股已出售。该公司还准备在行使认股权证时首次发行最多6,512,087股普通股，以及二次发行最多9,850,363股普通股和最多2,411,848份认股权证。Prosomnus, Inc. 以制造用于治疗阻塞性睡眠呼吸暂停的精密、大规模定制的口服器械治疗设备而闻名。该公司的普通股和公开认股权证分别在纳斯达克全球市场和纳斯达克资本市场上市，代码分别为...展开全部
2024年2月2日，特拉华州的一家公司ProSomnus, Inc. 向美国证券交易委员会（SEC）提交了S-3表格S-1的生效后修正案。该修正案旨在将原始注册声明转换为S-3表格的注册声明，并将先前注册的可转换票据股票从注册中删除，其中230,494股已出售。该公司还准备在行使认股权证时首次发行最多6,512,087股普通股，以及二次发行最多9,850,363股普通股和最多2,411,848份认股权证。Prosomnus, Inc. 以制造用于治疗阻塞性睡眠呼吸暂停的精密、大规模定制的口服器械治疗设备而闻名。该公司的普通股和公开认股权证分别在纳斯达克全球市场和纳斯达克资本市场上市，代码分别为 “OSA” 和 “OSAAW”。截至2024年1月29日，普通股和公开认股权证的收盘价分别为0.82美元和0.035美元。ProsomNus已宣布自己为 “新兴成长型公司” 和 “小型申报公司”，这可能使其能够遵守降低的上市公司在本次和未来申报中的报告要求。
有用
没用